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The aims of your case report is to show the predictivity of 99mTc-sestamibi (MIBI) scintigraphy and doppler ultrasound imaging
on secondary hyperparathyroidism (SHPT) in a patient responsive to calcimimetic treatment. Moreover, it has been reported
that calcimimetic has great potential in reducing the volume of the parathyroid gland. On the other hand, the MIBI scintigraphy
is considered a crucial diagnostic procedure to monitor the response to therapy in terms of turnover and cellular metabolism;
whereas, ultrasound to monitor the volume variation in response to treatment. It is described the case of a 73-year-old man on
hemodialysis from 1995 for ESRD. Within 2 years the patient gradually developed SHPT with progressively increased iPTH up to
1,000ρg/ml. The ultrasound, highlighted the presence of two parathyroid hyperplasia, conﬁrmed by scintigraphy, showing focal
increase uptake of sestamibi in the same anatomical areas. As a result of the patient’s refusal to perform a parathyroidectomy,
cinacalcet, was administered (65mg overage daily dose). After a year of treatment, there was a striking decrease of iPTH (from
1300 to 57ρg/ml, −95%); but, on the contrary to expectations, this positive metabolic outcome, was not followed by parathyroid
changes in ultrasound and scintigraphic ﬁndings.
1.Introduction
Over the past two years, the introduction of new drug
molecules, including new phosphate binders, less-calcemic
vitamin D analogues and calcimimetic, have been under-
going an incisive therapeutic change in the treatment of
secondary hyperparathyroidism in haemodialysis patients.
The novel vitamin D analogs, paracalcitol, doxercalciferol
and others as well as calcitriol and alfacalcidol, all decrease
serum PTH eﬃciently, but they also have a tendency
to increase serum phosphorus and serum calcium [1].
Cinacalcet is a type II calcimimetic agent, that acts as
an allosteric modulator of the calcium-sensing receptor,
which is present on the surface of parathyroid cells, thus
providing a new means of regulating PTH secretion, by
amplifying the receptor’s sensitivity to extracellular calcium
and reducing PTH concentrations. Cinacalcet has the same
marked decrease in serum PTH as active vitamin D sterols;
however, it causes a decrease of serum calcium and a
minor reduction in serum phosphorus [2]. Sesta MIBI
parathyroid scintigraphy is a routine imaging technique in
the assessment of haemodialysis patients, not only to identify
the autonomous glands requiring parathyroidectomy, but
also to detect those hyperplastic parathyroids which can be
suppressed by medical treatment.
A clinical case of full biochemical response to cal-
cimimetics therapy with successive regression in parathyroid
volume and functionality not being present was reported.
2. Case History
A 73-year-old man, began dialysis treatment in 1995, as a
result of a 10-year record of chronic kidney disease (CKD)
stage II, caused by hypertensive nephroangiosclerosis. The2 International Journal of Endocrinology
technique of extracorporeal therapy consisted of an endoge-
nous hemodiaﬁltration (HFR) with polyethersulfone mem-
branes, rythm dialysis was four hours x 3/weeks dialysate:
Na: 140mmol/L, K: 2mmol/L, bicarbonate: 30mmol/L, and
calcium: 1.5mmol/L.
In 1997 a mild secondary hyperparathyroidism (SHPT)
was detected and serum intact parathyroid hormone (iPTH)
was repeatedly found at 386.5ρg/ml, (normal range 10
to 65ρg/ml, IRMA Scantibody Radim) with no associated
speciﬁc symptoms. Checks by Chest X-ray, echocardiogram
high-resolution computerized tomography (CT) reported
an early detection of large and small vessels calciﬁcations,
including sclerodegenerative phenomena on aortic and
mitral endothelium valves, despite patient dietary cooper-
ation (there was rare evidence of hyperphosphoremia in
over 10 years of dialysis also owing to a large use of seve-
lamer and calcium carbonate). The patient presented other
comorbidities: osteoporosis and severe arthritis (former
semiprofessional athlete); an early dialysis amyloidosis with
consequentBaker’scystlocatedinthepoplitealfossa,positive
for amyloid. In the same period and as a consequence of
the same cause, the patient underwent bilateral neurolysis
of the median nerve for carpal tunnel syndrome. No liver
disease or haematologic and autoimmune diseases were
present.
From 2001 to 2004 the patient started oral pulses therapy
with calcitriol at dose of 1μg three times a week without
any change in iPTH levels (iPTH = 500ρg/ml). Due to a
lack of response to treatment, calcitriol therapy was given
intravenously at the same dose (1μg three times/week). The
iPTH showing a hyperfunctioning parathyroid gland and
continued to rise and after a year it rose up to values of
1,000ρg/ml and serum alkaline phosphatase activity also
increased progressively (see Table 1). Doppler ultrasonogra-
phy showed two enlarged inferior parathyroid glands with
hypervascularity (Figure 1), and two hot spots were detected
at the same location by
99mTc-MIBI scintigraphy (Figure 2).
Surgical treatment (subtotal parathyroidectomy) was pro-
posed, but the patient repeatedly refused; therefore, we
decided to initiate therapy with cinacalcet. Before beginning
cinacalcet, and without changing conventional therapy (a
constant dose of vitamin D and phosphate binders and
receiving a stable dialysate calcium concentration), blood
tests were performed to determine complete blood counts,
protein electrophoresis, 25(OH)2D3, iPTH, calcium, phos-
phorus, ionised calcium concentration, and bone turnover
markers (bone-speciﬁc alkaline phosphatase, osteocalcin).
Parathyroid MIBI scintigraphy and ultrasound scanning
were done at baseline, and after a year of treatment to
evaluate glandular function and structure (Tables 2(a) and
2(b)). In November 2005 oral treatment with cinacalcet was
initiated at a daily dose of 60mg.
The patient continued to receive the same low dose of
vitamin D sterols and phosphate binders.
During the 12 months, conventional therapy (phos-
phate binders, vitamin D sterol and calcium supplements)
and cinacalcet was adjusted, in order to try to achieve
and maintain National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI) (targets for
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PTH(150–300ρg/ml),serumcalcium(8.4–9.5mg/dl),phos-
phorus (3.5–5.5mg/dl), and calcium-phosphorus product
(<55mg2/dl2)). Dialysate calcium concentration and the
size of the dialyzer membrane surface area were not to
be changed. In a year of closed followup, serum iPTH
values progressively decreased with a good control of serum
phosphorus and normal serum calcium values persisted. In
December 2006, after a year of treatment with cinacalcet,
iPTHlevelswerefoundat57ρg/mlwithareductionof −95%
from the starting value (see Table 1).
Followingneckultrasoundperformance,after12months
of cinacalcet therapy, there was the conﬁrmation of the pres-
ence of two inferior parathyroid enlargements. The size and
echographic features of these lesions remained unchanged,
compared with the ultrasound images obtained before
treatment. Similarly,
99mTc-MIBI parathyroid scintigraphy
conﬁrmed hyperfunctioning parathyroid tissue (Table 2(b)).International Journal of Endocrinology 3
Table 1: Outcome of haematochemical and therapeutic parameters.
Start December
2005
January–March
2006 (monthly
average)
April–June 2006
(monthly
average)
July–September
2006 (monthly
average)
End December
2006
iPTH, ρg/ml 1112 821 156 125 57
alkaline phosp. U/L 173 112 142 108 107
bone Alkal. phosp. U/L 66.4 27.3 15.9 12 10
calcium, mg/dL 9.1 9.3 7.8 8.2 9.4
phosphorus, mg/dL 5.6 4.3 4.9 4.6 4.9
ionized calcium,
mmol/L 1.16 1.22 1.15 1.14 1.22
cinacalcet, average g/die 60 60 60 45 30
Calcium carbonate,
g/die 2.5 5 5 3.3 1.2
Sevelamer, g/die 11.2 7.7 6.4 6.4 4.8
Calcitriol, μg/sett/os 0.75 0.75 0.75 0.75 0.75
Table 2
(a) Scintigraphic and echographic features at the start before calcimimetic administration
Basal study
99mTc-MIBI scintigraphy: 2 parathyroid glands
scintigraphic features
(1) Focal area of increased radiotracer uptake was present posteriorly to the lower
pole of the right thyroid lobe
(2) Another smaller area of increased radiotracer uptake was present inferiorly to
the lower pole of the left thyroid lobe
CD ultrasound: 2 parathyroid glands
Echographic features
(1) Nonhomogeneous hypoechoic capsulated area with a vascular pole was present
posteriorly to the lower pole of the right thyroid lobe. The major three axes of the
parathyroid glands were 13.8 ×10.0 × 8.0mm
(2) Non homogeneous hypoechoic capsulated area with a vascular pole was present
inferiorly to the lower pole of the left thyroid lobe. The major three axes of the
parathyroid gland were 8 ×5 ×3mm
(b) Scintigraphic and echographic features after one year of calcimimetic administration
After 1 year of cinacalcet therapy
99mTc-MIBI scintigraphy 2 parathyroid glands
Scintigraphic features The focal areas of increased radiotracer uptake were unmodiﬁed respect to basal
control.
CD ultrasound 2 parathyroid glands
Echographic features
(1) Echographic structure of the lesion present posteriorly to the lower right pole of
the thyroid lobe was unmodiﬁed. The major three axes of the parathyroid gland
were 11 ×10 ×8mm
(2) Echographic lesion inferiorly to the lower pole of the left thyroid lobe was
unmodiﬁed respect to basal control
Further follow-up was not made possible due to the patient’s
death of myocardial infarction three months later.
3. Discussion
Clinical evaluation of SHPT is usually carried out by the
assessment of biochemical parameters and morphological
and functional imaging. In recent years, various techniques
including ultrasound (US), CT, magnetic resonance and
MIBI-scintigraphy have been used to localize better enlarged
parathyroid glands in patients with SHPT, although MIBI
scintigraphy appears to be the most speciﬁc in recur-
rent/persistent SHPT [3–5]. Calcimimetics have become
available for the treatment of dialysis patients with insuﬃ-
ciently controlled SHTP as well as calcium and/or phosphate4 International Journal of Endocrinology
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levels on conventional therapies. Cinacalcet belongs to
calcimimetic type II compounds that can interact with
the calcium-sensing receptor CaSR, increasing its aﬃnity
to calcium. Clinical studies have proved cinacalcet to be
eﬀective in reducing calcium, phosphate, and PTH levels in
haemodialysis patients with severe SHPT [6–9]. Colloton
et al. [10] reported that cinacalcet inhibits the progres-
sion of parathyroid cell proliferation in rats. Meola et
al. [11] described morphological ultrasound variations in
hyperplastic parathyroid glands in haemodialysis patients
treated with cinacalcet. They observed changes in vol-
ume, vascularisation, and sonographic patterns after 12–
18 months of therapy and volume reduction was more
evident in gland with basal volume <0.5cm3.I na g r e e -
ment with these ﬁndings, parathyroid size regression after
cinacalcet treatment has been recently reported in [12].
The literature is not yet clear if the inhibitory eﬀect of
cinacalcet on PTH secretion is associated with an eﬀective
control of parathyroid cell metabolism turnover, specially
in parathyroid >0.5cm3 [13]. In our knowledge no data
has been reported about the relationship between metabolic
changes and MIBI uptake in haemodialysis patients treated
with calcimimetic therapy; MIBI is a lipophilic radiotracer
that becomes concentrated in cells and in mitochondria
through active transport and passive diﬀusion. The exact
mechanism of its elective uptake in abnormal parathyroid
glands remains debatable. The size of abnormal parathyroid
does not represent the only determinant of MIBI uptake
but other factors including the mitochondria numbers,
degree of cellular activity, and glycoprotein P expression
have been described in [14–17]. Piga et al. [18] stated that
MIBI scans do not simply reveal parathyroid enlargement
but rather identify hyperfunctioning parathyroid glands in
patientswithSHPT.AdditionalevidencethatMIBIshowsthe
functional status of parathyroids is found in the correlation
between MIBI uptake and intact PTH in SHPT [19, 20].
Moreover, Torregrosa et al. [21] demonstrated that high
MIBI uptake is correlated with the G2/S (active growth)
phase.
It was shown that MIBI-scan could be used to evaluate
parathyroid function as well as response to treatment
with calcitriol [22, 23]. In our case with positive basal
MIBI-scan after the inhibition test with calcitriol (2μg
i.v. three times/week for two weeks after haemodialysis),
we could suppose two diﬀerent scintigraphic ﬁndings: (1)
lack of parathyroid MIBI-uptake suggestive of a reduction
in metabolic activity of parathyroid glands, selecting the
responders, and (2) persistence of MIBI uptake indicative
of parathyroid functional autonomy, selecting the candidate
patients for surgery.
In our patient the calcitriol, administered in low weekly
not pulsing dose to correct hypocalcemia induced by cal-
cimimetic, was not able to inhibit parathyroid hyperplasia.
There were not detected high levels of phosphorus as
a factor in stimulating hyperplasia [24]. In our case is
excluded another but uncommon possibility that ultrasound
and scintigraphic could be explained due to a mutation
in enzyme CYP3A4 or described using other inhibitor
drugs (e.g., ketoconazole, erythromycin, itraconazole) on
this enzyme which could interfere in the therapeutic eﬃcacy
of calcimimetic [25]. We conclude that a
99mTc-MIBI
parathyroid scan could not have showed a good correlation
to the response of the cinacalcet treatment. In our case
contrary to allexpectations unchanging parathyroid MIBI
uptake appears seemingly to be in contrast to the inhibitory
eﬀect of calcimimetic, on parathyroid hormone secretion.
Possible hypothesis to explain this paradoxical result may
be the eﬀect of cinacalcet on Ca receptors. In fact this
drug increasing the membrane sensitivity to cations, as
calcium, my induce a consequent increase of other cations,
as MIBI, resulting in abnormal parathyroid uptake of MIBI
independent of a real cellular function.
In conclusion in our case report we believe that
99mTc-
MIBI scintigraphy remains to be deﬁned as a useful method
inmonitoringandpredictingeﬃcacyinlong-termcinacalcet
therapy, in uremic patients; as well, it remains to be deﬁned
the meaning of sestamibi uptake, as an index of metabolic
turn-over of the parathyroid glands. Instead doppler ultra-
sonography may represent a good marker to evaluate the
regression of volume glandular. However; up until present
day, there is not any clear illustration of a modiﬁcation of
the metabolic turnover of the parathyroid gland produced
by using calcimimetic agents: surgical and histopathological
conﬁrmations should be necessary in more cases.International Journal of Endocrinology 5
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